Effects of unplanned treatment interruptions on HIV treatment failure - results from TAHOD

被引:9
作者
Jiamsakul, Awachana [1 ]
Kerr, Stephen J. [1 ,2 ,3 ]
Ng, Oon Tek [4 ]
Lee, Man Po [5 ]
Chaiwarith, Romanee [6 ]
Yunihastuti, Evy [7 ]
Kinh Van Nguyen [8 ]
Thuy Thanh Pham [9 ]
Kiertiburanakul, Sasisopin [10 ]
Ditangco, Rossana [11 ]
Saphonn, Vonthanak [12 ,13 ]
Sim, Benedict L. H. [14 ]
Merati, Tuti Parwati [15 ,16 ]
Wong, Wingwai [17 ]
Kantipong, Pacharee [18 ]
Zhang, Fujie [19 ]
Choi, Jun Yong [20 ]
Pujari, Sanjay [21 ]
Kamarulzaman, Adeeba [22 ]
Oka, Shinichi [23 ]
Mustafa, Mahiran [24 ]
Ratanasuwan, Winai [25 ]
Petersen, Boondarika [26 ]
Law, Matthew [1 ]
Kumarasamy, Nagalingeswaran [27 ]
机构
[1] UNSW Australia, Kirby Inst, Sydney, NSW, Australia
[2] Thai Red Cross AIDS Res Ctr, HIV NAT, Bangkok, Thailand
[3] Univ Amsterdame, Acad Med Ctr, Amsterdam Inst Global Hlth & Dev, Dept Global Hlth, Amsterdam, Netherlands
[4] Tan Tock Seng Hosp, Dept Infect Dis, Singapore, Singapore
[5] Queen Elizabeth Hosp, Hong Kong, Hong Kong, Peoples R China
[6] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand
[7] Univ Indonesia, Working Grp AIDS, Fac Med, Cipto Mangunkusumo Hosp, Jakarta, Indonesia
[8] Natl Hosp Trop Dis, Hanoi, Vietnam
[9] Bach Mai Hosp, Hanoi, Vietnam
[10] Mahidol Univ, Ramathibodi Hosp, Fac Med, Bangkok 10400, Thailand
[11] Res Inst Trop Med, Manila, Philippines
[12] Natl Ctr HIV AIDS Dermatol & STDs, Phnom Penh, Cambodia
[13] Univ Hlth Sci, Phnom Penh, Cambodia
[14] Hosp Sungai Buloh, Sungai Buloh, Malaysia
[15] Udayana Univ, Fac Med, Bali, Indonesia
[16] Sanglah Hosp, Bali, Indonesia
[17] Taipei Vet Gen Hosp, Taipei, Taiwan
[18] Chiangrai Prachanukroh Hosp, Chiang Rai, Thailand
[19] Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China
[20] Yonsei Univ, Coll Med, Dept Internal Med, Div Infect Dis, Seoul, South Korea
[21] Inst Infect Dis, Pune, Maharashtra, India
[22] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia
[23] Natl Ctr Global Hlth & Med, Tokyo, Japan
[24] Hosp Raja Perempuan Zainab II, Kota Baharu, Malaysia
[25] Mahidol Univ, Fac Med, Siriraj Hosp, Bangkok 10700, Thailand
[26] amfAR Fdn AIDS Res, TREAT Asia, Bangkok, Thailand
[27] YRGCARE Med Ctr, Madras, Tamil Nadu, India
基金
美国国家卫生研究院;
关键词
HIV; treatment interruptions; adverse events; Asia; antiretroviral; ACTIVE ANTIRETROVIRAL THERAPY; VIROLOGICAL FAILURE; DRUG-RESISTANCE; FOLLOW-UP; IMMUNOLOGICAL RESPONSE; OBSERVATIONAL DATABASE; POSITIVE INDIVIDUALS; TREATMENT OUTCOMES; INFECTED PATIENTS; ADHERENCE;
D O I
10.1111/tmi.12690
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
ObjectivesTreatment interruptions (TIs) of combination antiretroviral therapy (cART) are known to lead to unfavourable treatment outcomes but do still occur in resource-limited settings. We investigated the effects of TI associated with adverse events (AEs) and non-AE-related reasons, including their durations, on treatment failure after cART resumption in HIV-infected individuals in Asia. MethodsPatients initiating cART between 2006 and 2013 were included. TI was defined as stopping cART for >1 day. Treatment failure was defined as confirmed virological, immunological or clinical failure. Time to treatment failure during cART was analysed using Cox regression, not including periods off treatment. Covariables with P < 0.10 in univariable analyses were included in multivariable analyses, where P < 0.05 was considered statistically significant. ResultsOf 4549 patients from 13 countries in Asia, 3176 (69.8%) were male and the median age was 34 years. A total of 111 (2.4%) had TIs due to AEs and 135 (3.0%) had TIs for other reasons. Median interruption times were 22 days for AE and 148 days for non-AE TIs. In multivariable analyses, interruptions >30 days were associated with failure (31-180 days HR = 2.66, 95%CI (1.70-4.16); 181-365 days HR = 6.22, 95%CI (3.26-11.86); and >365 days HR = 9.10, 95% CI (4.27-19.38), all P < 0.001, compared to 0-14 days). Reasons for previous TI were not statistically significant (P = 0.158). ConclusionsDuration of interruptions of more than 30 days was the key factor associated with large increases in subsequent risk of treatment failure. If TI is unavoidable, its duration should be minimised to reduce the risk of failure after treatment resumption.
引用
收藏
页码:662 / 674
页数:13
相关论文
共 44 条
  • [1] Abdissa Senbeta Guteta, 2012, Ethiop Med J, V50, P107
  • [2] Anderson J, 2008, AIDS, V22, P349, DOI 10.1097/QAD.0b013e3282f4709a
  • [3] Sustained HIV viral suppression following treatment interruption: An observational study
    Bedimo, R
    Chen, RY
    Westfall, AO
    Raper, JL
    Allison, JJ
    Saag, MS
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2006, 22 (01) : 40 - 44
  • [4] Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients
    Cicconi, P.
    Cozzi-Lepri, A.
    Castagna, A.
    Trecarichi, E. M.
    Antinori, A.
    Gatti, F.
    Cassola, G.
    Sighinolfi, L.
    Castelli, P.
    Monforte, A. d'Arminio
    [J]. HIV MEDICINE, 2010, 11 (02) : 104 - 113
  • [5] Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses
    Crawford, K. W.
    Wakabi, S.
    Magala, F.
    Kibuuka, H.
    Liu, M.
    Hamm, T. E.
    [J]. HIV MEDICINE, 2015, 16 (02) : 95 - 104
  • [6] Determinants of virological failure after 1 year's antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces
    Dam Anh Tran
    Wilson, David P.
    Shakeshaft, Anthony
    Anh Duc Ngo
    Doran, Christopher
    Zhang, Lei
    [J]. SEXUALLY TRANSMITTED INFECTIONS, 2014, 90 (07) : 538 - 544
  • [7] El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360
  • [8] Eluwa George I, 2012, BMC Clin Pharmacol, V12, P7, DOI 10.1186/1472-6904-12-7
  • [9] Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen
    Fox, Zoe
    Phillips, Andrew
    Cohen, Cal
    Neuhaus, Jacquie
    Baxter, John
    Emery, Sean
    Hirschel, Bernard
    Hullsiek, Kathy Huppler
    Stephan, Christoph
    Lundgren, Jens
    [J]. AIDS, 2008, 22 (17) : 2279 - 2289
  • [10] Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America
    Genberg, Becky L.
    Wilson, Ira B.
    Bangsberg, David R.
    Arnsten, Julia
    Goggin, Kathy
    Remien, Robert H.
    Simoni, Jane
    Gross, Robert
    Reynolds, Nancy
    Rosen, Marc
    Liu, Honghu
    [J]. AIDS, 2012, 26 (11) : 1415 - 1423